Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16954451 | 0.86 | DRD1 (0.38) | DRD1KDM4EMAPT | |
| SCHEMBL16962151 | 0.81 | KDM4E (0.35) | DRD1KDM4EPOLBMAPT | |
| SCHEMBL24036554 | 0.81 | DRD1 (0.49) | DRD1KDM4EPOLBMAPT | |
| SCHEMBL3163240 | 0.80 | ALOX15 (0.36) | DRD1KDM4EPOLBMAPT | |
| SCHEMBL3167719 | 0.79 | DRD1 (0.34) | DRD1 | |
| SCHEMBL16959465 | 0.78 | TP53 (0.38) | DRD1 | |
| SCHEMBL16962491 | 0.78 | CYP1B1 (0.47) | KDM4EMAPT | |
| SCHEMBL16953742 | 0.78 | DRD1 (0.33) | DRD1 | |
| SCHEMBL13787900 | 0.78 | MEN1 (0.34) | DRD1MAPT | |
| SCHEMBL16951819 | 0.78 | ALDH1A3 (0.36) | DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| US-7803954-B2 | Competitive and selective inhibitors of trypsin-like serine proteases involved in hemostasis; anticoagulants; Ph(3-Cl)(5-OCHF2) (R)CH(OH)C(O)-Aze-Pab(OMe); oral administration; gelling matrix modified-release system | ASTRAZENECA AB (SE) | 2010-09-28 | — | — | US | disclosed |
| EP-2186800-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | Astra Zeneca AB (SE) | 2010-05-19 | — | — | EP | disclosed |
| EP-1347955-B1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2010-03-17 | — | — | EP | disclosed |
| US-20070218136-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2007-09-20 | — | — | US | disclosed |
| US-20070202174-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2007-08-30 | — | — | US | disclosed |
| CN-1939903-A | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | CN | disclosed |
| CN-1939902-A | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2007-04-04 | — | — | CN | disclosed |
| CN-1291975-C | Novel mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | CN | disclosed |
| US-7129233-B2 | Mandelic acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2006-10-31 | — | — | US | disclosed |
| US-20060052314-A1 | Pharmaceutical combination | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | disclosed |
| CN-1656066-A | combination drug | ASTRAZENECA AB (SE) | 2005-08-17 | — | — | CN | disclosed |
| EP-1513807-A1 | PHARMACEUTICAL COMBINATION | AstraZeneca AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| CN-1487919-A | Novel mandelic acid derivatives and their use as thrombin inhibitors | — | 2004-04-07 | — | — | CN | disclosed |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2004-01-29 | — | — | US | disclosed |
| WO-2003101956-A1 | PHARMACEUTICAL COMBINATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| EP-1347955-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | AstraZeneca AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002044145-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ADAMTS1, ADAMTS13, ADAMTS7 | DRD1 1225/4885KDM4E 4650/4885POLB 1216/4885 |
| US-20070202174-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | TFPI, F2R, F2 | DRD1 3371/4885KDM4E 4282/4885POLB 3747/4885 |
| US-20060052314-A1 | Pharmaceutical combination | F2, TNNT2, WFS1 | DRD1 569/4885KDM4E 3871/4885POLB 4335/4885 |
| US-20070218136-A1 | New mandelic acid derivatives and their use as thrombin inhibitors | TFPI, F2R, F2 | DRD1 3371/4885KDM4E 4282/4885POLB 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.